Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Radiology
Published in: Pediatric Radiology 5/2008

Open Access 01-05-2008 | Review

Gadolinium and nephrogenic systemic fibrosis: time to tighten practice

Authors: Iosif A. Mendichovszky, Stephen D. Marks, Clare M. Simcock, Øystein E. Olsen

Published in: Pediatric Radiology | Issue 5/2008

Login to get access

Abstract

Nephrogenic systemic fibrosis (NSF) is a relatively new entity, first described in 1997. Few cases have been reported, but the disease has high morbidity and mortality. To date it has been seen exclusively in patients with renal dysfunction. There is an emerging link with intravenous injection of gadolinium contrast agents, which has been suggested as a main triggering factor, with a lag time of days to weeks. Risk factors include the severity of renal impairment, major surgery, vascular events and other proinflammatory conditions. There is no reason to believe that children have an altered risk compared to the adult population. It is important that the paediatric radiologist acknowledges emerging information on NSF but at the same time considers the risk:benefit ratio prior to embarking on alternative investigations, as children with chronic kidney disease require high-quality diagnostic imaging.
Literature
1.
Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001PubMedCrossRef
2.
Ting WW, Stone MS, Madison KC et al (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139:903–906PubMedCrossRef
3.
Jimenez SA, Artlett CM, Sandorfi N et al (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660–2666PubMedCrossRef
4.
Kucher C, Steere J, Elenitsas R et al (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54:S31–S34PubMedCrossRef
5.
6.
Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790PubMedCrossRef
7.
Mackay-Wiggan JM, Cohen DJ, Hardy MA et al (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55–60PubMedCrossRef
8.
Swartz RD, Crofford LJ, Phan SH et al (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563–572PubMedCrossRef
9.
Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765PubMedCrossRef
10.
Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209–212PubMed
11.
Neudecker BA, Stern R, Mark LA et al (2005) Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol 32:612–615PubMedCrossRef
12.
Solomon GJ, Wu E, Rosen PP (2007) Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. Arch Pathol Lab Med 131:145–148PubMed
13.
Obermoser G, Emberger M, Wieser M et al (2004) Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus 13:609–612PubMedCrossRef
14.
Maloo M, Abt P, Kashyap R et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 6:2212–2217PubMedCrossRef
15.
Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25:358PubMedCrossRef
16.
Quan TE, Cowper SE, Bucala R (2006) The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 8:145–150PubMedCrossRef
17.
Lauchli S, Zortea-Caflisch C, Nestle FO et al (2004) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208:278–280PubMedCrossRef
18.
Gilliet M, Cozzio A, Burg G et al (2005) Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152:531–536PubMedCrossRef
19.
Baron PW, Cantos K, Hillebrand DJ et al (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25:204–209PubMedCrossRef
20.
Kafi R, Fisher GJ, Quan T et al (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140:1322–1324PubMedCrossRef
21.
Chung HJ, Chung KY (2004) Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150:596–597PubMedCrossRef
22.
Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108PubMedCrossRef
23.
Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362PubMedCrossRef
24.
High WA, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21–26PubMedCrossRef
25.
Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27–30PubMedCrossRef
26.
Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157PubMedCrossRef
27.
Khurana A, Runge VM, Narayanan M et al (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42:139–145PubMedCrossRef
28.
Broome DR, Girguis MS, Baron PW et al (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 188:586–592PubMedCrossRef
29.
Kuo PH, Kanal E, Abu-Alfa AK et al (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647–649PubMedCrossRef
30.
31.
32.
Leiner T, Herborn CU, Goyen M (2007) Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 17:1921–1923PubMedCrossRef
33.
Collidge TA, Thomson PC, Mark PB et al (2007)Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.Radiology. DOI 2451070353
34.
Marckmann P, Skov L, Rossen K et al (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. DOI 10.​1093/​ndt/​gfm261
35.
Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502PubMedCrossRef
36.
Idee JM, Berthommier C, Goulas V et al (1998) Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 11:113–123PubMedCrossRef
37.
Corot C, Idee JM, Hentsch AM et al (1998) Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging 8:695–702PubMedCrossRef
38.
Behra-Miellet J, Gressier B, Brunet C et al (1996) Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 18:437–442PubMed
39.
Green RW, Krestin GP (2006) Non-tissue specific extra cellular MR contrast media. In: Thomsen HS (ed) Contrast media: safety issues and ESUR guidelines. Springer, Berlin, pp 107–112
40.
Idee JM, Port M, Raynal I et al (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576PubMedCrossRef
41.
Harpur ES, Worah D, Hals PA et al (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28 [Suppl 1]:S28–S43PubMedCrossRef
42.
Spencer AJ, Wilson SA, Batchelor J et al (1997) Gadolinium chloride toxicity in the rat. Toxicol Pathol 25:245–255PubMedCrossRef
43.
Mendoza FA, Artlett CM, Sandorfi N et al (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238–249PubMedCrossRef
44.
Itoh N, Kawakita M (1984) Characterization of Gd3+ and Tb3+ binding sites on Ca2+,Mg2+–adenosine triphosphatase of sarcoplasmic reticulum. J Biochem (Tokyo) 95:661–669
45.
Husztik E, Lazar G, Parducz A (1980) Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol 61:624–630PubMed
46.
Puttagunta NR, Gibby WA, Puttagunta VL (1996) Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol 31:619–624PubMedCrossRef
47.
Bartolini ME, Pekar J, Chettle DR et al (2003) An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis. Magn Reson Imaging 21:541–544PubMedCrossRef
48.
Krasnow N (1977) Lanthanide binding to cardiac and skeletal muscle microsomes. Effects of adenosine triphosphate, cations, and ionophores. Arch Biochem Biophys 181:322–330PubMedCrossRef
49.
Lansman JB (1990) Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit. J Gen Physiol 95:679–696PubMedCrossRef
50.
Jan F, Segal JM, Dyer J et al (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678–681PubMedCrossRef
51.
Jain SM, Wesson S, Hassanein A et al (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467–470PubMedCrossRef
52.
Dharnidharka VR, Wesson SK, Fennell RS (2007) Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 22:1395PubMedCrossRef
53.
DiCarlo JB, Gupta EA, Solomon AR (2006) A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J Am Acad Dermatol 54:914–916PubMedCrossRef
54.
Auron A, Shao L, Warady BA (2006) Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 21:1307–1311PubMedCrossRef
Metadata
Title
Gadolinium and nephrogenic systemic fibrosis: time to tighten practice
Authors
Iosif A. Mendichovszky
Stephen D. Marks
Clare M. Simcock
Øystein E. Olsen
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Pediatric Radiology / Issue 5/2008
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-007-0633-8

Other articles of this Issue 5/2008

Pediatric Radiology 5/2008 Go to the issue

Obituary

Dr. John C. Leonidas (September 8, 1930–January 24, 2008)

Original Article

Diagnostic performance of the upper gastrointestinal series in the evaluation of children with clinically suspected malrotation

Case Report

Neonatal pyruvate dehydrogenase deficiency due to a R302H mutation in the PDHA1 gene: MRI findings

Case Report

Pediatric extraskeletal osteosarcoma

Pediatric Radiology CME Activity

Pediatric Radiology Continuing Medical Education Activity

Clinical Image

Leukemia and treatment: imprint on the growing skeleton